What type of study is this?

September 10, 2025European Heart Journal Supplements

Immune checkpoint inhibitor-associated myocarditis: clinical characteristics, management, and outcomes from a tertiary cardio-oncology unit

View Full Paper

Ask AI

Bookmark

Authors

ARAlexandra Pons RiverolaBellvitge University Hospital MFM. FeliuInstitut d'Investigació Sanitària Pere Virgili SJSantiago Jiménez‐MarreroHeart Failure & Transplant

Discussion

Member takes

Implication

Descriptive analysis reveals high mortality and varied symptoms in patients with immune checkpoint inhibitor-associated myocarditis, suggesting a need for improved management strategies.

Key Points

Myocarditis developed in patients after using immune checkpoint inhibitors, with high mortality rates.
In-hospital mortality reached 31%, largely due to severe immune-related toxicity mechanisms.
Cardiac imaging, particularly with MRI, is essential for diagnosing ICI-related myocarditis effectively.
Extracardiac symptoms like myositis were present in many cases, complicating clinical management.

Cite This Study

Riverola et al. (2025) studied this question.

synapsesocial.com/papers/68c1a5e554b1d3bfb60df1fb https://doi.org/10.1093/eurheartjsupp/suaf083.151

View Full Paper

Ask AI

Bookmark

Implication

Descriptive analysis reveals high mortality and varied symptoms in patients with immune checkpoint inhibitor-associated myocarditis, suggesting a need for improved management strategies.

Immune checkpoint inhibitor-associated myocarditis: clinical characteristics, management, and outcomes from a tertiary cardio-oncology unit

Discussion

Member takes

Implication

Key Points

Cite This Study

Immune checkpoint inhibitor-associated myocarditis: clinical characteristics, management, and outcomes from a tertiary cardio-oncology unit

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider